These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31677454)

  • 1. Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease.
    Adesina OO; Jenkins IC; Wu QV; Fung EB; Narla RR; Lipkin EW; Mahajan K; Konkle BA; Kruse-Jarres R
    Blood Cells Mol Dis; 2020 Feb; 80():102369. PubMed ID: 31677454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis.
    Nur E; Mairuhu W; Biemond BJ; van Zanten AP; Schnog JJ; Brandjes DP; Otten HM;
    Am J Hematol; 2010 Nov; 85(11):902-4. PubMed ID: 20882525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
    Krishnamoorthy P; Alyaarubi S; Abish S; Gale M; Albuquerque P; Jabado N
    Pediatrics; 2006 Aug; 118(2):e537-9. PubMed ID: 16882790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study.
    Hierso R; Lemonne N; Villaescusa R; Lalanne-Mistrih ML; Charlot K; Etienne-Julan M; Tressières B; Lamarre Y; Tarer V; Garnier Y; Hernandez AA; Ferracci S; Connes P; Romana M; Hardy-Dessources MD
    Br J Haematol; 2017 Mar; 176(5):805-813. PubMed ID: 27984639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis.
    Garnero P; Delmas PD
    Bone; 2003 Jan; 32(1):20-6. PubMed ID: 12584032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
    van Zuuren EJ; Fedorowicz Z
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010155. PubMed ID: 26684281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary creatine: biochemical indicator for evaluation of sickle cell crises.
    Beyer C; Statius van Eps LW; Kastelein JJ; Brandjes DP; Mairuhu WM; van den Ende A
    Clin Chem; 1985 Jul; 31(7):1232-4. PubMed ID: 4006197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan.
    Olabode JO; Shokunbi WA
    West Afr J Med; 2006; 25(4):284-8. PubMed ID: 17402517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in urinary excretions of C-telopeptide and cross-linked N-telopeptide of type I collagen during pregnancy and puerperium.
    Yamaga A; Taga M; Minaguchi H
    Endocr J; 1997 Oct; 44(5):733-8. PubMed ID: 9466331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Biemond BJ; Tombak A; Kilinc Y; Al-Khabori M; Abboud M; Nafea M; Inati A; Wali Y; Kristensen J; Kowalski J; Donnelly E; Ohd J;
    Lancet Haematol; 2021 May; 8(5):e334-e343. PubMed ID: 33894169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
    van Zuuren EJ; Fedorowicz Z
    Cochrane Database Syst Rev; 2013 Jun; (6):CD010155. PubMed ID: 23760785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocalcin and specific markers of bone resorption in sickle cell disease.
    Bolarin DM; Azinge EC
    Acta Physiol Hung; 2010 Sep; 97(3):290-6. PubMed ID: 20843767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
    Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M; Uemura T; Minaguchi H
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.
    Deux JF; Audard V; Brugières P; Habibi A; Manea EM; Guillaud-Danis C; Godeau B; Galactéros F; Stehlé T; Lang P; Grimbert P; Audureau E; Rahmouni A; Bartolucci P
    Am J Kidney Dis; 2017 Jan; 69(1):51-59. PubMed ID: 27663041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis.
    Yaster M; Tobin JR; Billett C; Casella JF; Dover G
    Pediatrics; 1994 Feb; 93(2):310-5. PubMed ID: 8121746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
    Kawana K; Takahashi M; Hoshino H; Kushida K
    Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.